Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro

• Published in: Cancers Vol. 3; no. 1; pp. 1467 - 1479
• Main Authors: Olszewski, Ulrike, Liedauer, Richard, Ausch, Christoph, Thalhammer, Theresia, Hamilton, Gerhard
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.03.2011; Molecular Diversity Preservation International (MDPI)
• Subjects: ALDH1A1; Brain cancer; cancer stem cells; CD133; Cell culture; Cell cycle; Chemotherapy; colon cancer; Colorectal cancer; CYP3A4; DNA repair; Gene expression; Growth factors; Radiation therapy; Stem cells; Tumors; Austria
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers3011467

Cancer stem cells (CSCs) seem to constitute a subpopulation of tumor cells that escape from chemotherapy and cause recurrent disease. Low proliferation rates, protection in a stem cell niche and overexpression of drug resistance proteins are considered to confer chemoresistance. We established an in vitro colon CSC-like model using the COLO 205 cell line, which revealed transiently increased expression of CD133 when transferred to serum-free stem cell culture medium. Assessment of global gene expression of COLO 205 cells under these conditions identified a set of upregulated genes including cytochrome P450 3A4 (CYP3A4) and aldehyde dehydrogenase 1A1 (ALDH1A1), as confirmed by real-time qPCR. ALDH1A1 is a CSC marker for certain tumor entities and confers resistance to cyclophosphamide. CYP3A4 is expressed in liver and colon and its overexpression seems particularly relevant in colon cancer, since it inactivates irinotecan and other xenobiotics, such as taxols and vinca alkaloids. In conclusion, this COLO 205 model provides evidence for CD133 induction concomitant with overexpression of CYP3A4, which, together with ATP-binding cassette, subfamily G, member 2 (ABCG2) and others, may have a role in chemoresistant colon CSCs and a negative impact on disease-free survival in colon cancer patients.